99 related articles for article (PubMed ID: 17149721)
1. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation.
Nichols WC; Marek DK; Pauciulo MW; Pankratz N; Halter CA; Rudolph A; Shults CW; Wojcieszek J; Foroud T;
Mov Disord; 2007 Jan; 22(2):254-7. PubMed ID: 17149721
[TBL] [Abstract][Full Text] [Related]
2. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease.
Toft M; Mata IF; Ross OA; Kachergus J; Hulihan MM; Haugarvoll K; Stone JT; Blazquez M; Gibson JM; Aasly JO; White LR; Lynch T; Adler CH; Gwinn-Hardy K; Farrer MJ
Mov Disord; 2007 Feb; 22(3):389-92. PubMed ID: 17216639
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 mutations in a clinic-based cohort of Parkinson's disease.
Scholz S; Mandel RJ; Fernandez HH; Foote KD; Rodriguez RL; Barton E; Munson S; Singleton A; Okun MS
Eur J Neurol; 2006 Dec; 13(12):1298-301. PubMed ID: 17116211
[TBL] [Abstract][Full Text] [Related]
4. Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease.
Tan EK; Lee J; Chen CP; Wong MC; Zhao Y
Neurobiol Aging; 2009 Mar; 30(3):501-2. PubMed ID: 17720280
[TBL] [Abstract][Full Text] [Related]
5. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 gene in Parkinson disease: mutation analysis and case control association study.
Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E
Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8.
Nichols WC; Elsaesser VE; Pankratz N; Pauciulo MW; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T;
Neurology; 2007 Oct; 69(18):1737-44. PubMed ID: 17804834
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.
Johnson J; Paisán-Ruíz C; Lopez G; Crews C; Britton A; Malkani R; Evans EW; McInerney-Leo A; Jain S; Nussbaum RL; Foote KD; Mandel RJ; Crawley A; Reimsnider S; Fernandez HH; Okun MS; Gwinn-Hardy K; Singleton AB
Neurodegener Dis; 2007; 4(5):386-91. PubMed ID: 17622782
[TBL] [Abstract][Full Text] [Related]
9. Analysis of LRRK2 functional domains in nondominant Parkinson disease.
Skipper L; Shen H; Chua E; Bonnard C; Kolatkar P; Tan LC; Jamora RD; Puvan K; Puong KY; Zhao Y; Pavanni R; Wong MC; Yuen Y; Farrer M; Liu JJ; Tan EK
Neurology; 2005 Oct; 65(8):1319-21. PubMed ID: 16247070
[TBL] [Abstract][Full Text] [Related]
10. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
Nichols WC; Pankratz N; Hernandez D; Paisán-Ruíz C; Jain S; Halter CA; Michaels VE; Reed T; Rudolph A; Shults CW; Singleton A; Foroud T;
Lancet; 2005 Jan 29-Feb 4; 365(9457):410-2. PubMed ID: 15680455
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 R1441G in Spanish patients with Parkinson's disease.
Mata IF; Taylor JP; Kachergus J; Hulihan M; Huerta C; Lahoz C; Blazquez M; Guisasola LM; Salvador C; Ribacoba R; Martinez C; Farrer M; Alvarez V
Neurosci Lett; 2005 Jul; 382(3):309-11. PubMed ID: 15925109
[TBL] [Abstract][Full Text] [Related]
12. Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease.
Kay DM; Bird TD; Zabetian CP; Factor SA; Samii A; Higgins DS; Nutt J; Roberts JW; Griffith A; Leis BC; Montimurro JS; Philpott S; Payami H
Genet Test; 2006; 10(3):221-7. PubMed ID: 17020475
[TBL] [Abstract][Full Text] [Related]
13. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).
Ruiz-Martínez J; Gorostidi A; Ibañez B; Alzualde A; Otaegui D; Moreno F; López de Munain A; Bergareche A; Gómez-Esteban JC; Martí Massó JF
Mov Disord; 2010 Oct; 25(14):2340-5. PubMed ID: 20721916
[TBL] [Abstract][Full Text] [Related]
14. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
16. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian.
Carmine Belin A; Westerlund M; Sydow O; Lundströmer K; Håkansson A; Nissbrandt H; Olson L; Galter D
Mov Disord; 2006 Oct; 21(10):1731-4. PubMed ID: 16817197
[TBL] [Abstract][Full Text] [Related]
17. Lrrk2 R1628P variant is a risk factor for essential tremor.
Chao YX; Ng EY; Tan L; Prakash KM; Au WL; Zhao Y; Tan EK
Sci Rep; 2015 Mar; 5():9029. PubMed ID: 25761573
[TBL] [Abstract][Full Text] [Related]
18. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease.
Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G
Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
